Baseline data from a multicenter, 5-year, prospective cohort study of Japanese age-related macular degeneration: an AMD2000 report

Abstract

Purpose

To report research participants’ baseline characteristics in the AMD2000 study, a prospective, multicenter, 5-year, observational cohort study of Japanese age-related macular degeneration (AMD). The characteristics were determined using multimodal imaging.

Methods

Patients with AMD were recruited at 18 clinical sites in Japan between April 2006 and March 2009. Each patient underwent a complete ophthalmic examination, including measurement of best-corrected visual acuity (Landolt chart), indirect ophthalmoscopy, slit-lamp biomicroscopy with a contact lens, optical coherence tomography imaging, fundus photography, and fluorescein and indocyanine green angiography.

Results

Four hundred sixty participants (326 men [70.9%]) were included in the study. At enrollment, 131 eyes (28.5%) had hard drusen and 125 eyes (27.2%) had soft drusen in the macular area. A total of 455 eyes (98.9%) were diagnosed as having wet AMD, and 5 eyes (1.1%), as having dry AMD. Of the 455 eyes with wet AMD, 209 eyes (45.4%) had typical AMD, 228 eyes (49.6%) had polypoidal choroidal vasculopathy (PCV), and 18 eyes (3.9%) had retinal angiomatous proliferation. The size of choroidal neovascularization (CNV) was significantly smaller with indocyanine green angiography than with fluorescein angiography (P < 0.001). Poor baseline visual acuity was associated with cystoid macular edema, older age, scar, extrafoveal macular edema, subfoveal CNV, large branching vascular network, and hard exudates.

Conclusion

Japanese patients with AMD are predominantly male, lack drusen, and have a high rate of PCV.

This is a preview of subscription content, log in to check access.

Fig. 1

References

  1. 1.

    Bressler NM, Bressler SB, Fine SL. Age-related macular degeneration. Surv Ophthalmol. 1988;32:375–413.

    CAS  Article  PubMed  Google Scholar 

  2. 2.

    Bird AC, Bressler NM, Bressler SB, Chisholm IH, Coscas G, Davis MD, et al. An international classification and grading system for age-related maculopathy and age-related macular degeneration: the International ARM Epidemiological Study Group. Surv Ophthalmol. 1995;39:367–74.

    CAS  Article  PubMed  Google Scholar 

  3. 3.

    Danis RP, Lavine JA, Domalpally A. Geographic atrophy in patients with advanced dry age-related macular degeneration: current challenges and future prospects. Clin Ophthalmol. 2015;9:2159–74.

    Article  PubMed  PubMed Central  Google Scholar 

  4. 4.

    Wong CW, Yanagi Y, Lee WK, Ogura Y, Yeo I, Wong TY, et al. Age-related macular degeneration and polypoidal choroidal vasculopathy in Asians. Prog Retin Eye Res. 2016;53:107–39.

    Article  PubMed  Google Scholar 

  5. 5.

    Oishi A, Tsujikawa A, Yamashiro K, Ooto S, Tamura H, Nakanishi H, et al. One-year result of aflibercept treatment on age-related macular degeneration and predictive factors for visual outcome. Am J Ophthalmol. 2015;159(853–60):e1.

    Google Scholar 

  6. 6.

    Saito M, Kano M, Itagaki K, Sekiryu T. Efficacy of intravitreal aflibercept in Japanese patients with exudative age-related macular degeneration. Jpn J Ophthalmol. 2017;61:74–83.

    CAS  Article  PubMed  Google Scholar 

  7. 7.

    Hosokawa M, Morizane Y, Hirano M, Kimura S, Kumase F, Shiode Y, et al. One-year outcomes of a treat-and-extend regimen of intravitreal aflibercept for polypoidal choroidal vasculopathy. Jpn J Ophthalmol. 2017;61:150–8.

    CAS  Article  PubMed  Google Scholar 

  8. 8.

    Macular Photocoagulation Study Group. Subfoveal neovascular lesions in age-related macular degeneration: guidelines for evaluation and treatment in the macular photocoagulation study. Arch Ophthalmol. 1991;109:1242–57.

    Article  Google Scholar 

  9. 9.

    Verteporfin in Photodynamic Therapy Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization: verteporfin in photodynamic therapy report 2. Am J Ophthalmol. 2001;131:541–60.

    Article  Google Scholar 

  10. 10.

    Iijima H, Imai M, Gohdo T, Tsukahara S. Optical coherence tomography of idiopathic polypoidal choroidal vasculopathy. Am J Ophthalmol. 1999;127:301–5.

    CAS  Article  PubMed  Google Scholar 

  11. 11.

    Tsujikawa A, Sasahara M, Otani A, Gotoh N, Kameda T, Iwama D, et al. Pigment epithelial detachment in polypoidal choroidal vasculopathy. Am J Ophthalmol. 2007;143:102–11.

    Article  PubMed  Google Scholar 

  12. 12.

    Zhang J, Yu Z, Liu L. Multimodality imaging in diagnosing polypoidal choroidal vasculopathy. Optom Vis Sci. 2015;92:e21–6.

    Article  PubMed  Google Scholar 

  13. 13.

    Semoun O, Coscas F, Coscas G, Lalloum F, Srour M, Souied EH. En face enhanced depth imaging optical coherence tomography of polypoidal choroidal vasculopathy. Br J Ophthalmol. 2016;100:1028–34.

    Article  PubMed  Google Scholar 

  14. 14.

    Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials—TAP report. Arch Ophthalmol. 1999;117:1329–45.

  15. 15.

    Yannuzzi LA, Sorenson J, Spaide RF, Lipson B. Idiopathic polypoidal choroidal vasculopathy (IPCV). Retina. 1990;10:1–8.

    CAS  Article  PubMed  Google Scholar 

  16. 16.

    Guyer DR, Yannuzzi LA, Slakter JS, Sorenson JA, Hanutsaha P, Spaide RF, et al. Classification of choroidal neovascularization by digital indocyanine green videoangiography. Ophthalmology. 1996;103:2054–60.

    CAS  Article  PubMed  Google Scholar 

  17. 17.

    Sato T, Kishi S, Watanabe G, Matsumoto H, Mukai R. Tomographic features of branching vascular networks in polypoidal choroidal vasculopathy. Retina. 2007;27:589–94.

    Article  PubMed  Google Scholar 

  18. 18.

    Grossniklaus HE, Gass JD. Clinicopathologic correlations of surgically excised type 1 and type 2 submacular choroidal neovascular membranes. Am J Ophthalmol. 1998;126:59–69.

    CAS  Article  PubMed  Google Scholar 

  19. 19.

    Japanese Study Group of Polypoidal Choroidal Vasculopathy. Criteria for diagnosis of polypoidal choroidal vasculopathy [in Japanese]. Nippon Ganka Gakkai Zasshi. 2005;109:417–27.

    Google Scholar 

  20. 20.

    Yannuzzi LA, Negrao S, Iida T, Carvalho C, Rodriguez-Coleman H, Slakter J, et al. Retinal angiomatous proliferation in age-related macular degeneration. Retina. 2001;21:416–34.

    CAS  Article  PubMed  Google Scholar 

  21. 21.

    Mitchell P, Smith W, Attebo K, Wang JJ. Prevalence of age-related maculopathy in Australia: the Blue Mountains Eye Study. Ophthalmology. 1995;102:1450–60.

    CAS  Article  PubMed  Google Scholar 

  22. 22.

    Hirami Y, Mandai M, Takahashi M, Teramukai S, Tada H, Yoshimura N. Association of clinical characteristics with disease subtypes, initial visual acuity, and visual prognosis in neovascular age-related macular degeneration. Jpn J Ophthalmol. 2009;53:396–407.

    Article  PubMed  Google Scholar 

  23. 23.

    Miyazaki M, Nakamura H, Kubo M, Kiyohara Y, Oshima Y, Ishibashi T, et al. Risk factors for age related maculopathy in a Japanese population: the Hisayama study. Br J Ophthalmol. 2003;87:469–72.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  24. 24.

    Yasuda M, Kiyohara Y, Hata Y, Arakawa S, Yonemoto K, Doi Y, et al. Nine-year incidence and risk factors for age-related macular degeneration in a defined Japanese population: the Hisayama study. Ophthalmology. 2009;116:2135–40.

    Article  PubMed  Google Scholar 

  25. 25.

    La TY, Cho E, Kim EC, Kang S, Jee D. Prevalence and risk factors for age-related macular degeneration: Korean National Health and Nutrition Examination Survey 2008–2011. Curr Eye Res. 2014;39:1232–9.

    CAS  Article  PubMed  Google Scholar 

  26. 26.

    Cheung CM, Li X, Cheng CY, Zheng Y, Mitchell P, Wang JJ, et al. Prevalence, racial variations, and risk factors of age-related macular degeneration in Singaporean Chinese, Indians, and Malays. Ophthalmology. 2014;121:1598–603.

    Article  PubMed  Google Scholar 

  27. 27.

    Rudnicka AR, Kapetanakis VV, Jarrar Z, Wathern AK, Wormald R, Fletcher AE, et al. Incidence of late-stage age-related macular degeneration in American whites: systematic review and meta-analysis. Am J Ophthalmol. 2015;160(85–93):e3.

    Google Scholar 

  28. 28.

    Klein R, Klein BE, Linton KL. Prevalence of age-related maculopathy: the Beaver Dam Eye Study. Ophthalmology. 1992;99:933–43.

    CAS  Article  PubMed  Google Scholar 

  29. 29.

    Oshima Y, Ishibashi T, Murata T, Tahara Y, Kiyohara Y, Kubota T. Prevalence of age related maculopathy in a representative Japanese population: the Hisayama study. Br J Ophthalmol. 2001;85:1153–7.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  30. 30.

    Nakata I, Yamashiro K, Nakanishi H, Akagi-Kurashige Y, Miyake M, Tsujikawa A, et al. Prevalence and characteristics of age-related macular degeneration in the Japanese population: the Nagahama study. Am J Ophthalmol. 2013;156(1002–9):e2.

    Google Scholar 

  31. 31.

    Uyama M, Matsubara T, Fukushima I, Matsunaga H, Iwashita K, Nagai Y, et al. Idiopathic polypoidal choroidal vasculopathy in Japanese patients. Arch Ophthalmol. 1999;117:1035–42.

    CAS  Article  PubMed  Google Scholar 

  32. 32.

    Iwama D, Tsujikawa A, Sasahara M, Hirami Y, Tamura H, Yoshimura N. Polypoidal choroidal vasculopathy with drusen. Jpn J Ophthalmol. 2008;52:116–21.

    Article  PubMed  Google Scholar 

  33. 33.

    Maruko I, Iida T, Saito M, Nagayama D, Saito K. Clinical characteristics of exudative age-related macular degeneration in Japanese patients. Am J Ophthalmol. 2007;144:15–22.

    Article  PubMed  Google Scholar 

  34. 34.

    Otani A, Sasahara M, Yodoi Y, Aikawa H, Tamura H, Tsujikawa A, et al. Indocyanine green angiography: guided photodynamic therapy for polypoidal choroidal vasculopathy. Am J Ophthalmol. 2007;144:7–14.

    CAS  Article  PubMed  Google Scholar 

  35. 35.

    Akagi-Kurashige Y, Tsujikawa A, Oishi A, Ooto S, Yamashiro K, Tamura H, et al. Relationship between retinal morphological findings and visual function in age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2012;250:1129–36.

    Article  PubMed  Google Scholar 

  36. 36.

    Yannuzzi LA, Wong DW, Sforzolini BS, Goldbaum M, Tang KC, Spaide RF, et al. Polypoidal choroidal vasculopathy and neovascularized age-related macular degeneration. Arch Ophthalmol. 1999;117:1503–10.

    CAS  Article  PubMed  Google Scholar 

  37. 37.

    Imamura Y, Engelbert M, Iida T, Freund KB, Yannuzzi LA. Polypoidal choroidal vasculopathy: a review. Surv Ophthalmol. 2010;55:501–15.

    Article  PubMed  Google Scholar 

  38. 38.

    MacCumber MW, Dastgheib K, Bressler NM, Chan CC, Harris M, Fine S, et al. Clinicopathologic correlation of the multiple recurrent serosanguineous retinal pigment epithelial detachments syndrome. Retina. 1994;14:143–52.

    CAS  Article  PubMed  Google Scholar 

Download references

Acknowledgements

We are grateful to all the patients and coinvestigators for their cooperation in the current study. A list of the participating research sites and investigators is given in the Appendix. The authors also thank the following additional investigators at the Translational Research Informatics Center (TRI) at the Foundation for Biomedical Research and Innovation for their contributions to this trial: Ms Emiko Uno for data management; Ms Yasuko Kimura for project management; and Dr Hideaki Kaneda, Dr Shinsuke Kojima, Mr Mikio Yoshidomi, and Dr Atsuhiko Kawamoto for manuscript review.

Author information

Affiliations

Authors

Consortia

Corresponding author

Correspondence to Akitaka Tsujikawa.

Ethics declarations

Conflicts of Interest

A. Tsujikawa, Grant (Alcon, AMO Japan, Bayer, HOYA, Kowa, Novartis, Pfizer, Santen, Senju), Lecture fees (Alcon, AMO Japan, Bayer, Chugai, Kowa, Nidek, Novartis, Pfizer, Santen, Sanwa Kagaku, Senju); Y. Akagi-Kurashige, None; M. Yuzawa, Grant (Alcon Japan, Santen), Consultant fees (Alcon Japan, Astellas Pharma, Janssen Japan), Lecture fees (Astellas Pharma, Bausch & Lomb Japan, Bayer, Japan Focus Company, Novartis, Santen, Senju); T. Ishibashi, None; H. Nakanishi, None; E. Nakatani, None; S. Teramukai, Grant (Daiichi Sankyo), Consultant fee (Daiichi Sankyo, Sanofi, Solasia Pharma, Sysmex, Taiho Pharmaceutical), Lecture fees (Bristol-Myers Squibb, Fujifilm); M. Fukushima, None; N. Yoshimura, None.

Additional information

The members listed in the AMD2000 Study Group are given in Appendix.

Appendix

Appendix

Principal investigator: Nagahisa Yoshimura (Kyoto University Hospital).

Coprincipal investigator: Tatsuro Ishibashi (Kyushu University Hospital) and Mitsuko Yuzawa (Surugadai Nihon University Hospital).

Research sites and investigators: Sapporo City General Hospital, Hokkaido (Muneyasu Takeda, Hiroko Imaizumi, Utako Okushiba); Hirosaki University Hospital, Aomori (Mitsuru Nakazawa, Yukihiko Suzuki); Yamagata University Hospital, Yamagata (Hidetoshi Yamashita, Daijiro Tsuchiya); Gunma University Hospital, Gunma (Shoji Kishi, Ryo Mukai, Maki Takahashi, Taku Sato, Hidetaka Matsumoto); Tokyo Medical University Ibaraki Medical Center, Ibaraki (Masahiro Miura); Surugadai Nihon University Hospital, Tokyo (Mitsuko Yuzawa, Ryuzaburo Mori); Tokyo University Hospital, Tokyo (Yasuhiro Tamaki, Ryo Obata, Yasuo Yanagi); Tokyo Medical University Hospital, Tokyo (Takuya Iwasaki, Yasuyuki Yamauchi); Yokohama City University Medical Center, Kanagawa (Kazuaki Kadonosono, Maiko Inoue, Misa Suzuki); Seirei Hamamatsu General Hospital, Shizuoka (Akira Obana); Fujita Health University Hospital, Aichi (Masayuki Horiguchi, Atsuhiro Tanikawa); Kyoto University Hospital, Kyoto (Nagahisa Yoshimura, Akitaka Tsujikawa, Hideo Nakanishi, Yumiko Akagi-Kurashige, Kenji Yamashiro, Atsushi Otani, Hiroshi Tamura, Ayako Takahashi, Akio Oishi); Osaka University Hospital, Osaka (Fumi Gomi, Miki Sawa); Osaka Medical College Hospital, Osaka (Tsunehiko Ikeda, Masahiro Minami); Kansai Medical University Hospital, Osaka (Kanji Takahashi); Kansai Medical University Takii Hospital, Osaka (Kenichiro Sho); Kobe University Hospital, Hyogo (Shigeru Honda); Kagoshima University Medical and Dental Hospital, Kagoshima (Taiji Sakamoto, Akiko Okubo).

About this article

Verify currency and authenticity via CrossMark

Cite this article

Tsujikawa, A., Akagi-Kurashige, Y., Yuzawa, M. et al. Baseline data from a multicenter, 5-year, prospective cohort study of Japanese age-related macular degeneration: an AMD2000 report. Jpn J Ophthalmol 62, 127–136 (2018). https://doi.org/10.1007/s10384-017-0556-3

Download citation

Keywords

  • Age-related macular degeneration (AMD)
  • Drusen
  • Multimodal imaging
  • International classification
  • Polypoidal choroidal vasculopathy